-
2023.03.17
J-Pharma Announces that Mr. Haruki Kusaka, the Director of Clinical Development, has obtained an international certification as a Specialist in Medicines Development
-
What's new
- J-Pharma Announces that Mr. Haruki Kusaka, the Director of Clinical Development, has obtained an international certification as a Specialist in Medicines Development 2023/03/17
- J-Pharma presented Japanese Phase II Trial of Nanvuranlat at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium 2023 Nanvuranlat met primary endpoint in Japanese Phase II Trial for patients with refractory, advanced biliary tract cancers 2023/01/23
- J-Pharma Announces Publication of Abstracts of updates on the Japanese Phase II Study of Nanvuranlat (Development code: JPH203) at the 2023 American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2023/01/18
- J-Pharma to Present at The 41th Annual J.P. Morgan Healthcare Conference 2023/01/12
- We are pleased to announce J-Pharmaʼs lead oncology product candidate, Nanvuranlat will feature at the upcoming ASCO Gastrointestinal Cancers Symposium, to be held in San Francisco on 19-21 January 2023. 2022/12/23
-
Monthly